Cytokine Receptor Product Solutions

Comprehensive Portfolio of Cell-based, Functional Assays for Cytokines Receptors

Cytokines are a group of proteins that play a critical role in regulating the immune system and inflammation. The dysregulation of cytokines is associated with a wide range of diseases, including autoimmune disorders, cancer, and infectious diseases. Cytokine receptors are critical for cellular and extracellular communication in mediating immunological responses.

These receptors include type 1 and 2 cytokine-like interleukins, GM-CSF, interferons, chemokines, TNFα, TGF-β, and the Ig superfamily receptor types. All cytokine receptors are associated with one or more members of JAK kinases that couple the ligand binding to tyrosine phosphorylation of various STAT family transcription factors to the receptor complex.

Cytokines play a key role in the cytokine storm, a pro-inflammatory immune response, causing hyperinflammation and includes various cytokines such as interleukins (ILs), GM-CSF, chemokines, TNFα and more.

Therapeutics that target cytokines or their receptors can modulate the immune response and potentially treat these diseases. While the development of these drugs is complex and time-consuming and requires a deep understanding of the immune system and the role of cytokines in disease pathogenesis, assays are available to advance this discovery faster.

Eurofins DiscoverX® offers a comprehensive portfolio of PathHunter® cell-based, mechanism of action (MOA)-reflective, functional assays to enable the study and targeting of cytokine receptors, covering over 85% of human interleukins (IL-1 to IL-37) and their receptors.

These assays are designed to be highly specific and reproducible, include a simple protocol, and have a large signal-to-noise ratio and matrix tolerance. These cytokine receptor assays have enabled their broad application in functional screening, functional characterization, QC lot release assays, and neutralizing antibody studies.

Product Highlights

  • Biologically Relevant - MOA-reflective, functional assays for monitoring cytokine receptor activation and dimerization
  • Qualified Bioassays – Accelerate your cytokine therapeutic release program with cytokine receptor bioassays qualified using approved therapeutics like *Actemra® (tocilizumab), Kineret® (anakinra), Leukine® (sargramostim), and Humira® (adalimumab)
  • Easy-to-run & Scalable – Homogeneous, simple, rapid protocol amenable to high-throughput formats for increased efficiency
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
* Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group; Kineret is a registered trademark, licensed by Swedish Orphan Biovitrum AB and marketed by Sobi, Inc.; Leukine is a registered trademark licensed to Genzyme Corporation; and Humira is a registered trademark AbbVie, Inc.

Eurofins DiscoverX’s cytokine receptor assays are available in multiple formats to measure receptor activation, dimerization, SH2-recruitment, IκB degradation, and STAT3 transcription. These formats include stable cell lines, research-grade eXpress assay kits, and ready-to-use bioassays that can be used from discovery through development and into commercial release and stability QC lot testing. Contact our custom development team for additional assay needs, including new targets, MOAs, or characterization.

Cell Lines and Ready-to-Use eXpress Assay & Bioassay Kits

LigandAssay MechanismCell LineBioassay Kit
(2- & 10-plate)
eXpress Kit
(2- & 10-Plate)
Ligand Synonyms
CLCF1Contact Us  CLCF1; BSF-3; BSF3; CISS2; CLC; NNT-1; NNT1; NR6
CNTFContact Us  CNTF; HCNTF
CTF1Contact Us  CTF1
G-CSFSH2 Recruitment93-0809C3 93-0809E3CP16M
93-0809E3CP16L
CSF3; G-CSF; GCSF
M-CSFCSF1R / CSF1R93-1061C3  CSF1; CSF-1; MCSF
GM-CSFCSFR2A / CSFR2B93-1078C393-1078Y3-00111
93-1078Y3-00112
View Qualification Data
 CSF2; GMCSF
IL-1αIkB degradation93-0538C15  IL1A; IL-1A; IL1; IL1-ALPHA; IL1F1
IL-1αIL-1R1 / IL-1RAP93-1032C393-1032Y3-00105
93-1032Y3-00106
View Qualification Data
93-1032E3CP5M
93-01032E3CP5L
IL1A; IL-1A; IL1; IL1-ALPHA; IL1F1
IL-1βIkB degradation93-0538C15  IL1B; IL-1; IL1-BETA; IL1F2
IL-1F10Contact Us  IL1F10; FIL1-theta; IL-1HY2; IL-38; IL1-theta; IL1HY2
IL-1RNIkB degradation93-0538C15  IL1RN; DIRA; ICIL-1RA; IL-1RN; IL-1ra; IL-1ra3; IL1F3; IL1RA; IRAP; MVCD4
IL-1RNIL-1R1 / IL-1RAP93-1032C393-1032Y3-00105
93-1032Y3-00106
View Qualification Data
93-1032E3CP5M
93-01032E3CP5L
IL1RN; DIRA; ICIL-1RA; IL-1RN; IL-1ra; IL-1ra3; IL1F3; IL1RA; IRAP; MVCD4
IL-2IL-2RB / IL-2RG93-0998C3 93-0998E3CP5M
93-0998E3CP5L
IL2; IL-2; TCGF; lymphokine
IL-2IL-2RB / IL-2RG / IL-2RA93-1003C393-1003Y3-00091
93-1003Y3-00092
93-1003Y3-00187
93-1003E3CP0M
93-1003E3CP0L
IL2; IL-2; TCGF; lymphokine
IL-3IL-3R / CD131 (CSF2RB)93-0969C1  IL3; IL-3; CD131; CD-131
IL-4IL-4R / IL-2RG93-0988C3 93-0988E3CP5M
93-0988E3CP5L
IL4; BCGF-1; BCGF1; BSF-1; BSF1; IL-4
IL-4IL-4R / IL-13R93-1000C3
93-1001C1
 93-1000E3CP5M
93-1000E3CP5L
93-1001E1CP0M
93-1001E1CP0L
IL4; BCGF-1; BCGF1; BSF-1; BSF1; IL-4
IL-5IL-5R / CSF2RB93-0972C3 93-0972E3CP0M
93-0972E3CP0L
IL5; EDF; IL-5; TRF
IL-6IL-6RA / IL-6ST93-1045C393-1045Y3-00043
93-1045Y3-00044
View Qualification Data
93-1045E3CP5M
93-1045E3CP5L
IL6; BSF2; HGF; HSF; IFNB2; IL-6
IL-7Signaling Reporter93-1173C055IL7; IL-7
IL-7IL-7R / IL-2RG93-0997C1393-0997Y13-00081
93-0997Y13-00082
93-0997E13CP0M
93-0997E13CP0L
IL7; IL-7
IL-8CXCR293-0202C2 93-0202E2CP2M
93-0202E2CP2L
CXCL8; GCP-1; GCP1; IL8; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1
IL-8CXCR193-0226C3 93-0226E3CP0M
93-0226E3CP0L
CXCL8; GCP-1; GCP1; IL8; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1
IL-9IL-9R / IL-2RG93-1036C1  IL9; HP40; IL-9; P40
IL-10IL-10RA / IL-10RB93-0985C393-0985Y3-00135
93-0985Y3-00136
93-0985E3CP0M
93-0985E3CP0L
IL10; CSIF; GVHDS; IL-10; IL10A; TGIF
IL-11IL-11R / IL-6ST93-1028C1  IL11; AGIF; IL-11
IL-11STAT3 Transcriptional Reporter93-1168C044  IL11; IL11
IL-12IL-12RB1 / IL-12RB293-1041C3 93-1041E3CP0M
93-1041E3CP0L
IL12, p70
IL-13IL-4R / IL-13R93-1000C3 93-1000E3CP5M
93-1000E3CP5L
93-1001E1CP0M
93-1001E1CP0L
IL13; IL-13; P600
IL-13IL-4R / IL-13R93-1001C1 93-1001E1CP0MIL13; IL-13; P600
IL-14Contact Us  TXLNA; IL14; TXLN
IL-15IL-2RB / IL-2RG93-0998C3Dimerization Assay
93-0998Y3 (3 sizes)
Reporter Assay
93-1178Y055 (3 sizes)
93-0998E3CP5M
93-0998E3CP5L
IL15; IL-15
IL-16Contact Us  IL16; LCF; NIL16; PRIL16; prIL-16
IL-17AIL-17RA / IL-17RC93-0999C3
93-0931C1
93-0999Y3-00053
93-0999Y3-00054
93-0999E3CP0M
93-0999E3CP0L
93-0931E1CP7M
93-0931E1CP7L
IL17A; CTLA8; IL-17; IL-17A; IL17
IL-17BContact Us   
IL-17CContact Us   
TNFαIL-17RD / TNFR293-1068C3 93-1068E3CP5M
93-1068E3CP5L
TNF-alpha
IL-17EIL-17RA / IL-17RB93-1105C3  IL25; IL17E
IL-17FIL-17RA / IL-17RC93-0999C3 93-0999E3CP0M
93-0999E3CP0L
IL-17F
IL-18IL-18R / IL-18RAcP93-1131C3  IL18; IGIF; IL-18; IL-1g; IL1F4
IL-20IL-20R1 / IL-20R293-1027C3 93-1027E3CP0M
93-1027E3CP0L
IL20; IL-20; IL10D; ZCYTO10
IL-20IL-22R / IL-20R2Contact Us  IL20; IL-20; IL10D; ZCYTO10
IL-21IL-21R / IL-2RG93-1035C3 93-1035E3CP0M
93-1035E3CP0L
IL21; CVID11; IL-21; Za11
IL-22IL-22R / IL-10RB93-1026C1 93-1026E1CP7M
93-1026E1CP7L
IL22; IL-21; IL-22; IL-D110; IL-TIF; ILTIF; TIFIL-23; TIFa; zcyto18
IL-23IL-23R / IL-12RB193-1007C3 93-1007E3CP0M
93-1007E3CP0L
IL23A; IL-23; IL-23A; IL23P19; P19; SGRF
IL-24IL-20R1 / IL-20R293-1027C3  IL24; C49A; FISP; IL10B; MDA7; MOB5;ST16
IL-24IL-22R / IL-20R2Contact Us  IL24; C49A; FISP; IL10B; MDA7; MOB5; ST16
IL-26IL-20R1 / IL-10RB93-1020C3 93-1020E3CP0M
93-1020E3CP0L
IL26; AK155; IL-26
IL-27IL-27RA / IL6ST93-1119C3  IL30, p28
IL-28AIFNLR1 / IL-10RB93-0993C3 93-0993E3CP5M
93-0993E3CP5L
IL28A, IFNL2
IL-28BIFNLR1 / IL-10RB93-0993C3 93-0993E3CP5M
93-0993E3CP5L
IL28B, IFNL3
IL-29IFNLR1 / IL-10RB93-0993C3 93-0993E3CP5M
93-0993E3CP5L
IFNL1; IL-29; IL29
IL-31OSMRb /IL-31RA93-1002C393-1002Y3-00083
93-1002Y3-00084
93-1002E3CP5M
93-1002E3CP5L
IL31; IL-31
IL-32Contact Us  IL32; IL-32alpha; IL-32beta; IL-32delta; IL-32gamma; NK4; TAIF; TAIFa; TAIFb; TAIFc; TAIFd
IL-33IL-1RL1 (ST2) / IL-1RAP93-1067C393-1067Y3-00079
93-1067Y3-00080
93-1067E3CP5M
93-1067E3CP5L
IL33; C9orf26; DVS27; IL1F11; NF-HEV; NFEHEV; RP11-575C20.2
IL-34CSF1R / CSF1R93-1061C3  IL34; C16orf77; IL-34
IL-35IL-12RB2 / IL-6STContact Us  IL-35
IL-36AIL-1RL2 / IL-1RAPContact Us  IL36A; FIL1; FIL1(EPSILON); FIL1E; IL-1F6; IL1(EPSILON); IL1F6
IL-36BIL-1RL2 / IL-1RAPContact Us  IL36B; FIL1; FIL1-(ETA); FIL1H; FILI-(ETA); IL-1F8; IL-1H2; IL1-ETA; IL1F8; IL1H2
IL-36CIL-1RL2 / IL-1RAPContact Us  IL36G; IL-1F9; IL-1H1; IL-1RP2; IL1E; IL1F9; IL1H1; IL1RP2
IL-36RNIL-1RL2 / IL-1RAPContact Us  IL-36RA; IL36RA
IL-37IL-18R / SIGIRRContact Us  IL37; FIL1; FIL1(ZETA); FIL1Z; IL-1F7; IL-1H; IL-1H4; IL-1RP1; IL-37; IL1F7; IL1H4; IL1RP1
LIFIL-6ST / LIFRContact Us  LIF; CDF; DIA; HILDA; MLPLI
NPContact Us  Neuropoietin
OSMOSMRb / IL-6ST93-1056C3  OSM; MGC20461
TNFαIL-17RD / TNFR293-1068C3 93-1068E3CP5M
93-1068E3CP5L
TNF-alpha
TSLPSignaling Reporter93-1182C055TSLPR; IL7R; CD127; IL7RA; CRLF2; CRL2Y
TSLPIL-7R / TSLP-R93-1019C13 93-1019E13CP25M
93-1019E13CP25L
TSLPR; IL7R; CD127; IL7RA; CRLF2; CRL2Y

PathHunter cytokine receptor assays are based on the Enzyme Fragment Complementation (EFC) technology. These assays allow for the measurement of receptor activation, dimerization, SH2-recruitment, IκB degradation, and STAT3 transcription through various assay modalities, ultimately allowing for therapeutic candidate screening, potency, and stability testing. Select assay principles for receptor dimerization and IκB protein degradation assays are shown below. For additional assay principles, refer to receptor kinasesignaling pathway reportertargeted protein degradation, and GPCR target and application pages.

PathHunter Tocilizumab Bioassay Assay Principle

Measure IL-1β induced heterodimerization of IL-1R1 and IL-1RAP receptors using the PathHunter Anakinra Bioassay (Cat. No. 93-1032Y3-00106) qualified with the FDA approved therapeutic Kineret (anakinra, an IL-1R antagonist being evaluated as potential therapeutic). The assay principle involves the complementing of PK and EA EFC fragments tagged to IL-1RAP and IL-R1, respectivitly. In presence of IL-1β, the receptors dimerize and there is an increase in signal detected upon substrate addition. However, in the presence of anakinra, the binding of IL-1β is inhibited and the signal decreases. Kineret® is a registered trademark, licensed by Swedish Orphan Biovitrum AB and marketed by Sobi, Inc.

PathHunter Anakinra Bioassay Assay Principle

Measure IL-1β induced heterodimerization of IL-1R1 and IL-1RAP receptors using the PathHunter Anakinra Bioassay (Cat. No. 93-1032Y3-00106) qualified with the FDA approved therapeutic Kineret (anakinra, an IL-1R antagonist being evaluated as potential therapeutic). The assay principle involves the complementing of PK and EA EFC fragments tagged to IL-1RAP and IL-R1, respectivitly. In presence of IL-1β, the receptors dimerize and there is an increase in signal detected upon substrate addition. However, in the presence of anakinra, the binding of IL-1β is inhibited and the signal decreases. Kineret® is a registered trademark, licensed by Swedish Orphan Biovitrum AB and marketed by Sobi, Inc.

PathHunter Sargramostim Bioassay Assay Principle

Measure GM-CSF induced heterodimerization of CSF2RA with CSF2RB PathHunter Sargramostim Bioassay Kit (Cat. No. 93-1078Y3-00112) qualified with the FDA approved therapeutic Leukin (sargramostim), which is being evaluated as potential therapeutic. The assay principle involves the complementing of PK and EA EFC fragments tagged to CSF2RB and CSF2RA, respectivitly. In presence of GM-CSF or sargramostim, the receptors dimerize and there is an increase in signal detected upon substrate addition. Leukine® is a registered trademark licensed to Genzyme Corporation.

PathHunter Adalimumab Bioassay Assay Principle

Detect IkB protein degradation as a result of TNFα-mediated activation of the NF-kB signaling pathway using PathHunter Adalimumab Bioassay Kit (Cat. No. 93-0538B15-00132) qualified with the FDA approved therapeutic Humira (adalimumab), which is being evaluated as potential therapeutic. The assay principle involves the enzyme donor ProLabel® (PL) tagged to phosphorylated IkB, and the IκB levels can then be measured by the addition of EA, which forces complementation of the two EFC fragments. The resulting active enzyme hydrolyzes the substrate to generate the signal that is proportional to the degree of IκB stabilization. In presence of TNFα, which activates the NF-kB signaling pathway, proteasome-mediated IκB degradation occurs and there is a loss of signal. In the presence of both TNFα and adalimumab, which blocks the binding of TNFα, degradation of IκB is avoided, and the EFC complementation occurs leading to an increase in signal upon substrate addition. Humira® is a registered trademark AbbVie, Inc.

Accurately Measure Receptor Activation with Highly Reproducable Bioassays for QC Lot Release

Tocilizumab Bioassay (Cat. No. 93-1045B3-00110) assessment of intra-day plate-to-plate and inter-day variability. Three experimental replicates of the assay were prepared as 11-point dose-response curves and run on the same plate with duplicate wells per dose on the same day by one operator. Results indicate 978, 960 and 997 ng/mL mean IC50’s for plates 1-3, respectively, and an overall 9.7% intermediate precision IC50. Similar experiments were repeated again to obtain data from three individual days (data not shown) for inter-day variability assessment with results showing an overall 1330 ng/mL mean IC50 and 24.6% intermediate precision IC50 for the 3 days. Results from both experiments for inter-plate and inter-day variability analysis show excellent uniformity demonstrating high reproducibility required for bioassay implementation in a QC environment for drug release.

Analyze Multiple Interleukin Receptor Families with Highly Specific Assays

Representative examples of assays for interleukin receptors from 6 different interleukin receptor families. Each plot shows a dose response for the relevant ligand(s) in a given assay from the indicated family. Data plotted are mean RLU and standard deviation from at least triplicate wells for each dose. These assays are characterized by robust assay windows and low CVs.

Quantify Anti-Receptor or Anti-Ligand Therapeutic Antibodies with Receptor Dimerization Assays

Reproducibly measure ligand-mediated receptor dimerization for potency and stability testing of therapeutics such as Kineret® (anakinra) implemented in QC lot release programs.

The PathHunter Anakinra Bioassay (Cat. No. 93-1032Y3-00106) was used to quantify an inhibitory response from Kineret (anakinra, an IL-1R antagonist being evaluated as potential therapeutic). A. In the presence of anakinra, there is a dose dependent inhibition (signal-to-background (S/B) 4.2; IC50 302 ng/mL) of IL-R1 and IL-1RAP dimerization. In comparison with agonist IL-1β, the receptors dimerize and there is an increase in signal detected (S/B 5.3; EC50 4.2 ng/mL). B. Dilutional linearity derived from the relative potency experiments performed over a range of 50-150%. Overall, the bioassay measures a robust response to both anakinra and IL-1β with a high accurate potency of over 99.4%. Kineret is a registered trademark, licensed by Swedish Orphan Biovitrum AB and marketed by Sobi, Inc.

Measure TNFα-Mediated Activation of the NF-κB Signaling Pathway with MOA-Reflective, IkB Protein Degradation Bioassays

The PathHunter Adalimumab Bioassay Kit (Cat. No. 93-0538B15-00132) was used to measure IκB protein degradation as a result of TNFα-mediated activation of the NF-kB signaling pathway. A. In the presence of adalimumab (Humira®), there is a dose dependent inhibition of TNFα-mediated activation IkB protein degradation and an increased signal (S/B 6.5; IC50 5.45 ng/mL). In comparison with TNFα alone, a decrease in signal detected (S/B 10.3; IC50 53.9 ng/mL). B. Dilutional linearity derived from the relative potency experiments performed over a range of 50-150%. Overall, the bioassay measures a robust response to both Humira and TNFα with an excellent accurate potency of over 99.99%. Humira is a registered trademark AbbVie, Inc.

Presentations [Cytokines Summit 2022] Enabling Cytokine Therapeutic Development with Qualified, Functional Cell-Based Assays

Gaurav Agrawal, Ph.D.Scientific Development Manager Discover how cell-based assays and translational services accelerate cytokine-based immunotherapeutic development from early discovery to…

Read More
Presentations [DOT 2020] Accelerate Your COVID-19 Drug Discovery with Qualified Cell-Based Assays for Proinflammatory Cytokines

Gaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX

Read More
Presentations [PEGS 2021] Accelerating Development of Therapeutic Interventions for COVID-19

Gaurav Agrawal, Ph.D. Scientific Development Manager Abstract Millions of deaths worldwide have been attributed to COVID-19, caused by the SARS-CoV-2…

Read More
Presentations [WCB 2020] Accelerate Your COVID-19 Drug Discovery with Qualified Cell-Based Assays for Proinflammatory Cytokines

Gaurav Agrawal, Ph.D. Scientific Development Manager, Eurofins DiscoverX

Read More
Presentations Advancing Therapeutics Targeting Cytokines with Functional Cell-based Assays

Jennifer Lin-Jones, Ph.D., Associate Director of Assay Development R&D Department, Eurofins DiscoverX

Read More

Scientific Posters Comprehensive & Fit-For-Purpose Solutions to Enable Drug Development for Cytokine Targets

Interleukins are known for their involvement in functioning of both the adaptive and innate immune systems. Interleukins direct immune cells…

Read More
Scientific Posters Building Robust and Simple Cell-Based Assays for Interleukins and Their Receptors

Ligand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional readout for Interleukin receptors.…

Read More
Scientific Posters New PathHunter Reporter Assays: Analysis of PD-1 Checkpoint Receptor and NFAT Signaling Pathways

Reporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit targets involved in specific…

Read More
Scientific Posters Immuno-Oncology Therapeutics Development Using PathHunter Signaling Pathway Reporter Assays

Reporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit or activate targets involved…

Read More
Scientific Posters Building Better Cell-Based Assays for Interleukins and Their Receptors

Ligand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…

Read More
Scientific Posters Detection of Cytokine and Growth Factor Receptor Dimerization Using Enzyme Fragment Complementation

Ligand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…

Read More
Scientific Posters Measuring Receptor Dimerization To Create Functional Cell-Based Assays for ~85% of the Interleukin Receptor Family

Ligand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…

Read More
Scientific Posters Detection of EGFR, HER2, HER3 and HER4 Hetero- and Homodimerization Using EFC-based Cellular Assays

Ligand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…

Read More
Scientific Posters Rapidly Develop Simple Potency Assays for Interleukins & Their Receptors

Ligand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…

Read More
Scientific Posters Identify Effective Therapeutics with Simple, Quantitative Cell-Based Assays That Measure Receptor Internalization

Both multi- and single-pass membrane receptors constitutively exhibit complicated and dynamic membrane receptor trafficking as well as internalization induced by…

Read More

Target Lists Products Target List

Comprehensive Eurofins DiscoverX product list to enable your drug discovery and development programs focused on checkpoint receptors, cytokine receptors/interleukins, cytotoxicity,…

Read More
Target Lists Cell-based Assays for Biologics Development Programs

Accelerate your biologics development from discovery to QC lot release with cell-based assays. Comprehensive list of bioassay kits, cell lines,…

Read More

Brochures & Flyers Targeted Protein Degradation Assays

Fast Cell-Based Assays for the Detection of Protein Turnover

Read More
Brochures & Flyers Accelerate Immuno-Oncology Drug Discovery & Development

Robust & Reproducible Cell-Based Assays for Potency Testing

Read More
Brochures & Flyers Expedite Cancer Drug Discovery & Development

Functional Cell-Based Assays, Cell Lines, & Proteins for Cancer Research Improved or novel small molecule or biologic therapeutics for cancer…

Read More
Brochures & Flyers High-Throughput Screening & Lead Optimization Products

Robust Cell-Based Assays to Identify Therapeutic Hits Rapidly

Read More
Brochures & Flyers Eurofins DiscoverX – Delivering Solutions from Discovery to Market

Products & Custom Development Capabilities.

Read More

Webinars Accelerating COVID-19 Drug Discovery: Qualified Cell-Based Assays for Proinflammatory Cytokines

COVID-19 has been declared a global pandemic by WHO. The disease is transmitted when the SARS-CoV-2 virus infects the respiratory…

Watch Now
Webinars Advancing Therapeutics Targeting Cytokines with Functional Cell-based Assays

Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.

Watch Now

Videos Reporter Assays for Therapeutics Targeting Signaling Pathways

Learn how PathHunter signaling reporter assays can be used to evaluate the cellular impact of therapeutics targeting a variety of…

Watch Now
Videos Accelerate Your COVID-19 Drug Discovery with Qualified Cell-Based Assays for Pro-inflammatory Cytokines

Learn how functional cell-based assays support COVID-19 drug discovery programs, particularly in managing proinflammatory cytokines associated with high mortality rate…

Watch Now
Videos Accelerating Immuno-Oncology Drug Discovery with MOA-Reflective, Functional Cell-Based Assays

Listen to the US PEGS 2023 conference talk by Venkatesh Chari, Ph.D. on MOA-reflective, functional cell-based assays (cell lines and…

Watch Now
Videos Custom Development Capabilities

Learn about Eurofins DiscoverX cell line engineering, assay development, and recombinant enzyme production custom capabilities. Find out more about cell…

Watch Now

Blogs & Articles Accelerating Cytokine Drug Discovery and QC Lot Release Testing with Qualified, Functional Cell-Based Assays

Cytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in…

Read More
Blogs & Articles Targeting Pro-Inflammatory Cytokines for COVID-19 Therapy: Cell-Based Assays for Accelerated Drug Discovery

The COVID-19 pandemic has left us racing against time for remediation. As a result, we have witnessed hundreds of therapeutic…

Read More
Receptor Tyrosine Kinase Assays

Functional & activity assays to analyze receptor dimerization, phosphorylation, internalization, & SH2-recruitment of RTKs & CTK/cytokine receptors

Read More
Signaling Reporter Assays

Simple, orthogonal reporter-based assays for screening & understanding therapeutic MOAs

Read More
Assays for COVID-19 Drug Discovery

Accelerate COVID-19 drug discovery & development programs targeting proinflammatory cytokines & others with qualified assays

Read More
Bioassays for Biologics

Ready-to-use kits for biologics characterization, MOA confirmation, NAbs detection, stability studies, & potency testing

Read More
GPCR Product Solutions

Cell-based assays to measure 2nd messengers (cAMP & calcium), β-arrestin recruitment, receptor internalization, & ligand binding

Read More
Build Your Own Assay Tools

Complete set of parental cell lines, vectors, kits, & retroparticles to build your own stable cell lines & cell-based assays

Read More
Custom Capabilities

Custom cell lines, kits, assays, & protein development capabilities optimized to fit your requirements

Read More
SPRINTer Targeted Protein Degradation Assays

Rapid cell-based assays for detecting protein turnover induced by targeted degrader molecules, such as PROTACs

Read More